Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
iptacopan - CFB inhibitor
Appendix
References
Innovation: Clinical trials
Abbreviations
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
NCT03955445 (CLNP023B12001B)
C3 glomerulopathy (C3G)
Phase 2
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT04817618 APPEAR-C3G (CLNP023B12301)
C3 glomerulopathy
Phase 3
68
27
Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine
collection)
Arms Intervention
Experimental: iptacopan 200mg b.i.d.
Placebo Comparator: Placebo to iptacopan 200mg b.i.d.
Patients with native C3G
Target Patients
Read-out Milestone(s)
2023
Publication
TBD
52 Investor Relations | Q1 2022 Results
Characterize the effect of LNP023 treatment on a composite renal response
endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in
proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit)
Open-label LNP023 200mg bid
Patients with C3 glomerulopathy
2025
Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR
trajectory
1 NOVARTIS | Reimagining MedicineView entire presentation